Latest Breaking News On - Tiago reis marques - Page 1 : comparemela.com

Pasithea Therapeutics Announces The First Cohort Has Completed The Initial Dosing In Its Phase 1 Trial Evaluating PAS-004 In RAS, NF1 And RAF Mutated

Pasithea Therapeutics Announces The First Cohort Has Completed The Initial Dosing In Its Phase 1 Trial Evaluating PAS-004 In RAS, NF1 And RAF Mutated
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesTiago reis marquesPasithea therapeutics corpExchange commissionWhile the companyChief executive officerSolid tumorsAmyotrophic lateral sclerosisPrivate securities litigation reform actAnnual reportQuarterly report

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position
sina.com.hk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.hk Daily Mail and Mail on Sunday newspapers.

United statesTiago reis marquesGraeme curriePatrick gaynesWhile the companyJones dayCorporate communicationsPasithea therapeutics corpExchange commissionStereoisomer patentsIssued extend portfolioStereoisomer patent filings continueExpand patent portfolioCentral nervous systemDevelopment officerExecutive officer

Pasithea Therapeutics Announces FDA Acceptance of IND

Pasithea s IND for PAS-004, a novel MEK inhibitor, is FDA-approved for Phase 1 trials in advanced cancer, starting Q1 2024 with early results by Q3..

United statesTiago reis marquesPatrick gaynesCorporate communicationsUs federal drug administrationPasithea therapeutics corpWhile the companyExchange commissionCentral nervous systemInvestigational new drug applicationDrug administrationChief executive officerEastern europeSolid tumorsAmyotrophic lateral sclerosisPrivate securities litigation reform act

Pasithea Therapeutics (KTTA) Announces FDA Acceptance of IND Application to Evaluate PAS-004

Pasithea Therapeutics (KTTA) Announces FDA Acceptance of IND Application to Evaluate PAS-004
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesTiago reis marquesPasithea therapeutics corpUs federal drug administrationPasithea therapeuticsCentral nervous systemInvestigational new drug applicationDrug administrationChief executive officerEastern europe

Baystreet ca - Pasithea Jumps as FDA Grants IND Status to Cancer Treatment

Pasithea Therapeutics Corp. (NASDAQ: KTTA) shares rise sharply first thing Tuesday. The San Francisco-based biotechnology company, focused on the discovery, research, and development of innovative treatments for Central Nervous System (CNS) disorders, .

United statesTiago reis marquesUs federal drug administrationPasithea therapeutics corpPasithea therapeuticsSan francisco basedCentral nervous systemInvestigational new drug applicationDrug administrationReis marquesEastern europe